JP3880265B2 - Aqueous solution of fat-soluble substances - Google Patents
Aqueous solution of fat-soluble substances Download PDFInfo
- Publication number
- JP3880265B2 JP3880265B2 JP32519299A JP32519299A JP3880265B2 JP 3880265 B2 JP3880265 B2 JP 3880265B2 JP 32519299 A JP32519299 A JP 32519299A JP 32519299 A JP32519299 A JP 32519299A JP 3880265 B2 JP3880265 B2 JP 3880265B2
- Authority
- JP
- Japan
- Prior art keywords
- fat
- soluble substance
- transmittance
- aqueous solution
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000126 substance Substances 0.000 title claims description 28
- 239000007864 aqueous solution Substances 0.000 title claims description 25
- 239000000243 solution Substances 0.000 claims description 34
- 238000002834 transmittance Methods 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 15
- 239000003995 emulsifying agent Substances 0.000 claims description 14
- 239000011709 vitamin E Substances 0.000 claims description 13
- 235000019165 vitamin E Nutrition 0.000 claims description 13
- 150000005846 sugar alcohols Polymers 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 6
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229950006156 teprenone Drugs 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019168 vitamin K Nutrition 0.000 claims description 2
- 239000011712 vitamin K Substances 0.000 claims description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- 229940110767 coenzyme Q10 Drugs 0.000 claims 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims 1
- 229960002167 sodium tartrate Drugs 0.000 claims 1
- 239000001433 sodium tartrate Substances 0.000 claims 1
- 235000011004 sodium tartrates Nutrition 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 31
- 239000000203 mixture Substances 0.000 description 23
- 238000009472 formulation Methods 0.000 description 18
- -1 fatty acid ester Chemical class 0.000 description 15
- 229930003427 Vitamin E Natural products 0.000 description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 11
- 229940046009 vitamin E Drugs 0.000 description 11
- 239000008213 purified water Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 229930003799 tocopherol Natural products 0.000 description 9
- 229960001295 tocopherol Drugs 0.000 description 9
- 239000011732 tocopherol Substances 0.000 description 9
- 235000010384 tocopherol Nutrition 0.000 description 9
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 230000035699 permeability Effects 0.000 description 8
- GZLGNNHEHXBCBI-UHFFFAOYSA-L [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O Chemical compound [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O GZLGNNHEHXBCBI-UHFFFAOYSA-L 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical group 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 229920000223 polyglycerol Polymers 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 150000005691 triesters Chemical class 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PHZOWSSBXJXFOR-UHFFFAOYSA-N 2-Propenyl glucosinolate Natural products OCC1OC(SC(CC=C)=NOS(O)(=O)=O)C(O)C(O)C1O PHZOWSSBXJXFOR-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- PHZOWSSBXJXFOR-MYMDCHNCSA-N Sinigrin Natural products S(=O)(=O)(O/N=C(\S[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)/CC=C)O PHZOWSSBXJXFOR-MYMDCHNCSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-M dec-9-enoate Chemical compound [O-]C(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-M 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- XSEOYPMPHHCUBN-FGYWBSQSSA-N hydroxylated lecithin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCC[C@@H](O)[C@H](O)CCCCCCCC XSEOYPMPHHCUBN-FGYWBSQSSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229940041290 mannose Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- QKFAFSGJTMHRRY-OCFLFPRFSA-M potassium;[(e)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylbut-3-enylideneamino] sulfate Chemical compound [K+].OC[C@H]1O[C@@H](S\C(CC=C)=N\OS([O-])(=O)=O)[C@H](O)[C@@H](O)[C@@H]1O QKFAFSGJTMHRRY-OCFLFPRFSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000017291 sinigrin Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000012438 synthetic essential oil Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Colloid Chemistry (AREA)
- General Preparation And Processing Of Foods (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は脂溶性物質の含水水性液剤、およびその製造方法に関する。
【0002】
【従来の技術】
一般に脂溶性物質は水に対して不溶性であり、食品や医薬品に添加する際に分離し不均一になりやすいという欠点がある。この点を解決するために、種々の試みがなされている。
例えば、特開昭62-250941号公報には、天然または合成の精油、色素、ビタミン、香料より選ばれる1種または2種以上よりなる非水溶性物質1〜70重量部に水酸基価970以下のポリグリセリンをモノ、ジ、トリエステル化して得られるポリグリセリン脂肪酸エステル1〜90重量部と水0.1〜50重量部および多価アルコール1〜90重量部を混合し可溶化することを特徴とする可溶化液の製造法が記載されている。
また、特開昭63-23811号公報には、乳化剤を含有する油相中に薬物を分散させ、注射用水を用いて乳化し、高圧ホモジナイザーを用いて均質化して得られる医薬製剤について開示されている。
さらに、特許2734520号公報には、脂溶性の薬理活性物質、全量の0.1〜3.0w/v%の油相成分並びにリン脂質および非イオン性界面活性剤を必須成分とする0.1〜20w/v%の乳化剤を2000kg/cm2以上の能力を有する高圧乳化機を用いて乳化することを特徴とする、平均粒子径が10nm以上40nm未満である微粒子脂肪乳剤の製造方法が開示されている。
【0003】
【発明が解決しようとする課題】
しかしながら、このようにして得られた製剤は、安定性や均一性、透明度の面から見ると未だ十分ではなく、さらに技術的に改良する必要があるものと考えられる。
したがって、本発明は長期間に渡って均一性が保たれ安定性が高く、しかも透明度の高い脂溶性物質の水性液剤およびその製造方法を提供することを目的とする。
【0004】
【課題を解決するための手段】
これらの状況から本発明者らは、鋭意研究を進めた結果、脂溶性物質に乳化剤、多価アルコールを加え均一化した後、高圧処理することによって上記の課題が解決できることを見出し、本発明を完成させた。
すなわち本発明は脂溶性物質を乳化剤、多価アルコールおよび水を攪拌混合した後、高圧処理することを特徴とする脂溶性物質水性液剤、およびその製造方法である。
【0005】
【発明の実施の形態】
本発明では、脂溶性物質にステアリン酸デカグリセリル、レシチン、リゾレシチン等の乳化剤、プロピレングリコール、ソルビトール等の多価アルコールおよび水を加え、ホモミキサー、コロイドミル等で均一化した後に、高圧ホモジナイザーを用いて高圧処理して水性液剤を調製する。
【0006】
本発明における脂溶性物質は医薬品、化粧品、食品等の原料物質として使用されるものであればいずれでもよく、特に限定されない。好ましくはテプレノン、ユビデカレノン、クロタミトン、ジフェンヒドラミン、リドカイン、ヒノキチオール等の薬剤として使用される脂溶性化合物、ビタミン類、エステル油、鉱物油、DHA、肝油、魚油、大豆油、ゴマ油、オリーブ油、月見草油、スクワラン、ヒマワリ油、しそ油等の油脂、カロチン、アナトー色素等の油溶性色素、ビタミンE、BHT、γ−オリザノール等の酸化防止剤、メントール、シオネール、ローズ油等の着香料、食品や健康食品、化粧品、医薬品等に使用される物質である。さらに好ましくはビタミンA、D、E、K等の脂溶性ビタミン、またはこれらの混合物である。
脂溶性物質の含有量は通常1〜40%、好ましくは5〜30%である。
【0007】
本発明において乳化剤とは、ラウリン酸デカグリセリル、ミリスチン酸デカグリセリル、パルミチン酸デカグリセリル、ステアリン酸デカグリセリル、アラキン酸デカグリセリル、ベヘン酸デカグリセリル、カプロレイン酸デカグリセリル、ラウロレイン酸デカグリセリル、ミリストレイン酸デカグリセリル、パルミトレイン酸デカグリセリル、オレイン酸デカグリセリル、バクセン酸デカグリセリル、リシノレイン酸デカグリセリル、ガドレイン酸デカグリセリル、リノール酸デカグリセリル、リノレン酸デカグリセリル、アラキドン酸デカグリセリル等のポリグリセリン脂肪酸エステル、レシチン、リゾレシチン、ヒドロキシル化レシチン、ケファリン、リゾケファリン、プラスマローゲン等のグリセロリン脂質、ショ糖脂肪酸エステル、ポリオキシエチレンソルビタン脂肪酸エステル等のポリオール系界面活性剤、ポリオキシエチレン硬化ヒマシ油等のポリオキシエチレン系界面活性剤、サポニン、シニグリン、ヘスペリジン、セレブロシド等の配糖体等を意味する。好ましくはステアリン酸デカグリセリル、オレイン酸デカグリセリル、レシチンおよびリゾレシチンである。なお、上記のポリグリセリン脂肪酸エステルは、モノエステル、ジエステル、トリエステルのうち1〜3種の混合物が好ましく、モノエステルにジエステル及び/又はトリエステルを混合したものがさらに好ましい。
これら乳化剤の含有量は、通常3〜50%、好ましくは5〜30%である。
【0008】
また、多価アルコールとしては、グリセリン、ジグリセリン、トリグリセリン、ポリグリセリン、プロピレングリコール、ジプロピレングリコール、1,3−ブチレングリコール、エチレングリコール、ポリエチレグリコール、ソルビトール、キシリトール、マルチトール、エリスリトール、マンニトール、キシロース、グルコース、ラクトース、マンノース等を使用することができる。好ましくは糖アルコールである。これら多価アルコールの含有量は、通常10〜90%、好ましくは30〜85%である。
これら多価アルコールは市販されている物を使用すればよい。例えば、本発明において使用したD-ソルビトール液、還元麦芽糖糖水飴液は約60〜80%の固形物と約20〜40%の水を含む液である。
【0009】
均一化する際に使用できるミキサーとしては、ホモミキサー、ホモジェッター、ポリトロンホモジナイザー、クレアミックス、ヒスコトロン等の高速攪拌機、プロペラ攪拌機、タービン攪拌機、コロイドミル、加圧乳化機等が挙げられる。均一化および高圧処理する際の温度範囲は、通常は常温から約90℃であり、好ましくは60〜80℃である。
また、高圧処理時の圧力範囲は限定されないが、通常は100〜5000kg/cm2であり、好ましくは500〜2000kg/cm2、さらに好ましくは750〜1800kg/cm2である。
【0010】
本発明に係る脂溶性物質の水性液剤は、医薬品、動物用医薬品、食品、健康食品、特定保険用食品、家畜用飼料、水産用飼料、ペットフード、ドリンク剤、抗酸化剤、化粧品配合剤、またはこれらに対する添加物として使用することができる。その際、水性液剤をそのまま用いることもでき、また公知の賦形剤を加えて、固形化することもできる。
医薬品として用いる場合には、エアゾル剤、チンキ剤、エキス剤、含漱剤、洗口液、エリキシル剤、ローション剤、点眼剤、点鼻剤、点耳剤、造影剤、経膣剤、経腸剤、軟膏剤、錠剤、チュアブル剤、顆粒剤、カプセル剤、液剤、シロップ剤、ゼリー剤、注射剤等とすることもできる。
また、食品の例としては、清涼飲料水、炭酸飲料、乳飲料、果実飲料、スポーツドリンク等の飲料、菓子、パン類、ハム、ベーコン、ソーセージ等の食肉加工製品、マーガリン等の油脂加工製品、こんぶ、素干品、煮干品等の水産加工品、ちくわ、かまぼこ等の水産ねり製品、麺類、食酢、みそ、しょうゆ等の発酵食品、さとう、はちみつ、でんぷん糖の糖類、冷蔵・冷凍食品、半調理・調理済食品、酒類、アイスクリーム類、経腸栄養食品などが挙げられる。
化粧品としては、香水、オーデコロン、浴用剤、制汗剤、歯磨剤、洗口液、化粧水、乳液、クリーム等の基礎化粧品、石鹸、皮膚洗浄料、毛髪用化粧品、ボディケア製品等を例示することができる。
【0011】
【実施例】
次に実施例を挙げて本発明を説明するが、本発明はこれらに限定されるものではない。
実施例1 各種ビタミンE水性液剤
表1に示した処方で、各成分を混合し、約70℃に加温しながら、ホモミキサーで10000rpm×5分間攪拌混合して、均一な水性液剤を調製した。この水性液剤を高圧乳化機を使用して、1000kg/cm2で高圧処理を行い、ミックストコフェロール水性液剤を得た。ミックストコフェロールとして、E mix A40(商品名、エーザイ(株)製、以下ミックストコフェロールと表記)、その他の成分は市販のものを用いた。
これらの高圧乳化処理液を、精製水または酸溶液(0.75%酒石酸-酒石酸ナトリウム緩衝液、pH3)で、ビタミンEとして0.01%の濃度になるように希釈し、640nmにおける透過率を測定した。また、それぞれの希釈液について、90℃で3分間の加熱処理を行った後の透過率、45℃で1カ月間静置した後の透過率も測定した。
その結果、いずれの処方においても良好な透過率を示した(表1)。
【0012】
【表1】
【0013】
次に、高圧処理を実施せず作製したビタミンE水性液剤の透過率を、比較例として以下に掲げる。
比較例1
表2に示した処方で、各成分を混合し、約70℃に加温しながら、ホモミキサーで10000rpm×5分間攪拌混合して、均一な水性液剤を調製した。
これらの水性液剤を、精製水または酸溶液(0.75%酒石酸-酒石酸ナトリウム緩衝液、pH3)でビタミンEとして0.01%の濃度になるように希釈し、640nmにおける透過率を測定した。また、それぞれの希釈液について、90℃で3分間の加熱処理を行った後の透過率も測定した。その結果、いずれの処方においても実施例1の処方と比較して、透過率は低くなる傾向を示した(表2)。
【0014】
【表2】
【0015】
以下に各種脂溶性薬物を使用した際の水性液剤の例と、組成成分や作製条件の違いによる影響等の例を掲げる。
実施例2 各種ビタミン水性液剤
表3に示した処方で実施例1と同様の方法を用いて、各種ビタミンの水性液剤を得た。これらの液剤について、精製水または酸溶液(0.75%酒石酸-酒石酸ナトリウム緩衝液、pH3)で、それぞれのビタミンとして0.01%の濃度になるように希釈し、640nmにおける透過率を測定した。また、それぞれの希釈液について、90℃で3分間の加熱処理を行った後の透過率も測定した。
その結果、各種ビタミン水性液剤の透過率は、いずれの処方においても良好であった(表3)。
【0016】
【表3】
【0017】
実施例3 各種脂溶性薬物の水性液剤
表4に示した処方で実施例1と同様の方法を用いて、各種脂溶性薬物の水性液剤を得た。これらの液剤について、精製水または酸溶液(0.75%酒石酸-酒石酸ナトリウム緩衝液、pH3)でそれぞれの薬物(処方13は大豆油)として0.01%の濃度になるように希釈し、640nmにおける透過率を測定した。また、それぞれの希釈液について、90℃で3分間の加熱処理を行った後の透過率も測定した。
その結果、各種脂溶性薬物水性液剤の透過率は、いずれの処方の場合にも良好であった(表4)。
【0018】
【表4】
【0019】
実施例4 処理圧力の違いによる透過率への影響
表5に示した処方で実施例1と同様の方法を用いて、ミックストコフェロールの水性液剤を得た。これらの液剤について、精製水でトコフェロールとして0.01%の濃度になるように希釈し、640nmにおける透過率を測定した。処理圧力は300、500、750、1000、1500および1800kg/cm2とした。その結果、500kg/cm2以上の圧力で処理すると好ましい結果が得られ、特に750kg/cm2以上の圧力で処理したものは、透過率が極めて良好であった。
【0020】
【表5】
【0021】
実施例5 脂肪酸鎖種の違いによる透過率への影響
表6に示した処方で実施例1と同様の方法を用いて、ミックストコフェロールの水性液剤を得た。これらの液剤について、精製水または酸溶液(0.75%酒石酸-酒石酸ナトリウム緩衝液、pH3)でそれぞれビタミンEとして0.01%の濃度になるように希釈し、640nmにおける透過率を測定した。また、それぞれの希釈液について、90℃で3分間の加熱処理を行った後の透過率も測定した。
その結果、脂肪酸鎖としてステアリン酸またはオレイン酸を使用したときには、液性、加熱処理に関係なく透過率は良好であった。ミリスチン酸またはラウリン酸を使用したときには、精製水で希釈したとき(加熱処理時を含む)および酸溶液で希釈した直後の透過率は良好であったが、酸溶液で希釈し、90℃で加熱処理をした場合には透過率は低下する傾向を示した(表6)。
【0022】
【表6】
【0023】
実施例6 レシチンまたはリゾレシチンを用いたビタミンE水性液剤
表7に示した処方で実施例1と同様の方法を用いて、ミックストコフェロールの水性液剤を得た。これらの液剤について、精製水または酸溶液(0.75%酒石酸-酒石酸ナトリウム緩衝液、pH3)でそれぞれビタミンEとして0.01%の濃度になるように希釈し、640nmにおける透過率を測定した。また、それぞれの希釈液について、90℃で3分間の加熱処理を行った後の透過率も測定した。
その結果、いずれの処方においても透過率は良好であった(表7)。
【0024】
【表7】
【0025】
実施例7 多価アルコールの違いによる透過率への影響
表8に示した処方で実施例1と同様の方法を用いて、ミックストコフェロールの水性液剤を得た。これらの液剤について、精製水または酸溶液(0.75%酒石酸-酒石酸ナトリウム緩衝液、pH3)でそれぞれビタミンEとして0.01%の濃度になるように希釈し、640nmにおける透過率を測定した。また、それぞれの希釈液について、90℃で3分間の加熱処理を行った後の透過率も測定した。
その結果、いずれの処方においても透過率は良好であった(表8)。
【0026】
【表8】
【0027】
実施例8 官能試験
表9および10に示した処方で実施例1と同様の方法を用いて、ミックストコフェロールの水性液剤を得た。また、表11に示した処方の市販品のビタミンE製剤を用意した。これらの液剤を、精製水または市販のドリンク剤で、それぞれビタミンEとして0.01%の濃度になるように希釈し、官能試験に供した。
4人の熟練したパネラーが、約20mlの各希釈液を約5秒間口に含んで吐き出し、味と香りを以下の4段階で評価した。◎:製品の風味に影響を与えない。○:製品の風味に対する影響は少ない。△:製品の風味に影響を与える。×:製品の風味に影響を与え、飲料用として適さない。
その結果を表9、10および11に示した。
【0028】
【表9】
【0029】
【表10】
【0030】
【表11】
[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a water-containing aqueous solution of a fat-soluble substance and a method for producing the same.
[0002]
[Prior art]
In general, fat-soluble substances are insoluble in water and have a drawback that they are easily separated and become non-uniform when added to foods and pharmaceuticals. Various attempts have been made to solve this problem.
For example, Japanese Patent Application Laid-Open No. 62-250941 discloses that 1 to 70 parts by weight of a water-insoluble substance consisting of one or more selected from natural or synthetic essential oils, pigments, vitamins and fragrances has a hydroxyl value of 970 or less. 1 to 90 parts by weight of polyglycerol fatty acid ester obtained by mono-, di- and triesterization of polyglycerol, 0.1 to 50 parts by weight of water and 1 to 90 parts by weight of polyhydric alcohol are mixed and solubilized. A method for producing a lysate is described.
JP-A-63-23811 discloses a pharmaceutical preparation obtained by dispersing a drug in an oil phase containing an emulsifier, emulsifying with water for injection, and homogenizing with a high-pressure homogenizer. Yes.
Further, Japanese Patent No. 2734520 discloses a fat-soluble pharmacologically active substance, 0.1 to 3.0 w / v% of the total amount of oil phase component, and 0.1 to 20 w / v% of phospholipid and nonionic surfactant as essential components. A method for producing a fine particle fat emulsion having an average particle diameter of 10 nm or more and less than 40 nm, characterized in that the emulsifier is emulsified using a high-pressure emulsifier having a capacity of 2000 kg / cm 2 or more is disclosed.
[0003]
[Problems to be solved by the invention]
However, the preparation thus obtained is still not sufficient from the viewpoint of stability, uniformity and transparency, and it is considered that further technical improvement is required.
Accordingly, an object of the present invention is to provide an aqueous liquid agent of a fat-soluble substance having a high degree of stability and a high degree of uniformity, and a method for producing the same, over a long period of time.
[0004]
[Means for Solving the Problems]
As a result of diligent research, the present inventors have found that the above problems can be solved by high-pressure treatment after adding an emulsifier and a polyhydric alcohol to a fat-soluble substance and homogenizing it. Completed.
That is, the present invention is a fat-soluble substance aqueous liquid preparation characterized by subjecting a fat-soluble substance to high-pressure treatment after stirring and mixing an emulsifier, a polyhydric alcohol and water, and a method for producing the same.
[0005]
DETAILED DESCRIPTION OF THE INVENTION
In the present invention, an emulsifier such as decaglyceryl stearate, lecithin and lysolecithin, a polyhydric alcohol such as propylene glycol and sorbitol, and water are added to the fat-soluble substance, and the mixture is homogenized with a homomixer, a colloid mill, etc., and then a high-pressure homogenizer is used. To prepare an aqueous liquid.
[0006]
The fat-soluble substance in the present invention is not particularly limited as long as it is used as a raw material substance for pharmaceuticals, cosmetics, foods and the like. Preferably fat-soluble compounds used as drugs such as teprenone, ubidecalenone, crotamiton, diphenhydramine, lidocaine, hinokitiol, vitamins, ester oil, mineral oil, DHA, liver oil, fish oil, soybean oil, sesame oil, olive oil, evening primrose oil, squalane , Oils and fats such as sunflower oil and perilla oil, oil-soluble pigments such as carotene and anato pigments, antioxidants such as vitamin E, BHT, and γ-oryzanol, flavoring agents such as menthol, thionel, and rose oil, foods and health foods, It is a substance used in cosmetics and pharmaceuticals. More preferred are fat-soluble vitamins such as vitamins A, D, E, and K, or a mixture thereof.
The content of the fat-soluble substance is usually 1 to 40%, preferably 5 to 30%.
[0007]
In the present invention, the emulsifier is decaglyceryl laurate, decaglyceryl myristate, decaglyceryl palmitate, decaglyceryl stearate, decaglyceryl arachiate, decaglyceryl behenate, decaglyceryl caproleate, lacaureate decaglyceryl, myristoleic acid Decaglyceryl, decaglyceryl palmitoleate, decaglyceryl oleate, decaglyceryl bacsenate, decaglyceryl ricinoleate, decaglyceryl gadoleate, decaglyceryl linoleate, decaglyceryl linolenate, decaglyceryl arachidonic acid, lecithin Glycerophospholipids such as lysolecithin, hydroxylated lecithin, kephalin, lysokephalin, plasmalogen, sucrose fatty acid ester Polyol based surfactants such as polyoxyethylene sorbitan fatty acid ester, refers to polyoxyethylene-based surfactants such as polyoxyethylene hydrogenated castor oil, saponins, sinigrin, hesperidin, a glycoside such as cerebrosides and the like. Preferred are decaglyceryl stearate, decaglyceryl oleate, lecithin and lysolecithin. In addition, said polyglyceryl fatty acid ester has preferable 1-3 types of mixtures among monoester, diester, and triester, and what mixed diester and / or triester in monoester is still more preferable.
The content of these emulsifiers is usually 3 to 50%, preferably 5 to 30%.
[0008]
In addition, as polyhydric alcohol, glycerin, diglycerin, triglycerin, polyglycerin, propylene glycol, dipropylene glycol, 1,3-butylene glycol, ethylene glycol, polyethylene glycol, sorbitol, xylitol, maltitol, erythritol, mannitol, Xylose, glucose, lactose, mannose and the like can be used. A sugar alcohol is preferred. The content of these polyhydric alcohols is usually 10 to 90%, preferably 30 to 85%.
These polyhydric alcohols may be commercially available. For example, the D-sorbitol solution and the reduced maltose syrup solution used in the present invention are solutions containing about 60 to 80% solids and about 20 to 40% water.
[0009]
Examples of the mixer that can be used for homogenization include a high speed stirrer such as a homomixer, a homojetter, a polytron homogenizer, Claremix, and Hiscotron, a propeller stirrer, a turbine stirrer, a colloid mill, and a pressure emulsifier. The temperature range during homogenization and high-pressure treatment is usually from room temperature to about 90 ° C, preferably 60 to 80 ° C.
Also, the pressure range during the high pressure treatment is not limited, is usually in 100~5000kg / cm 2, preferably not 500~2000kg / cm 2, more preferably a 750~1800kg / cm 2.
[0010]
Aqueous solutions of fat-soluble substances according to the present invention are pharmaceuticals, veterinary drugs, foods, health foods, foods for specified insurance, livestock feeds, marine feeds, pet foods, drinks, antioxidants, cosmetic ingredients, Or it can use as an additive with respect to these. At that time, the aqueous liquid agent can be used as it is, or it can be solidified by adding a known excipient.
When used as pharmaceuticals, aerosols, tinctures, extracts, mouthwashes, mouthwashes, elixirs, lotions, eye drops, nasal drops, ear drops, contrast agents, vaginal agents, enteral , Ointment, tablet, chewable, granule, capsule, liquid, syrup, jelly, injection and the like.
Examples of food include soft drinks, carbonated drinks, milk drinks, fruit drinks, sports drinks and other beverages, confectionery, breads, ham, bacon, sausage and other meat processed products, margarine and other fat and oil processed products, Seafood processed products such as kombu, dried fish, boiled and dried products, fishery products such as chikuwa, kamaboko, fermented foods such as noodles, vinegar, miso, soy sauce, sugar cane, honey, starch sugar, refrigerated / frozen foods, half Examples include cooked and cooked foods, alcoholic beverages, ice creams, and enteral nutrition foods.
Examples of cosmetics include perfumes, eau de cologne, bath preparations, antiperspirants, dentifrices, mouthwashes, lotions, emulsions, creams, and other basic cosmetics, soaps, skin cleansers, hair cosmetics, body care products, etc. be able to.
[0011]
【Example】
EXAMPLES Next, although an Example is given and this invention is demonstrated, this invention is not limited to these.
Example 1 Various Vitamin E Aqueous Solutions In the formulation shown in Table 1, each component was mixed and stirred and mixed with a homomixer at 10,000 rpm × 5 minutes while heating to about 70 ° C. to prepare a uniform aqueous solution. . This aqueous solution was subjected to a high-pressure treatment at 1000 kg / cm 2 using a high-pressure emulsifier to obtain a mixed tocopherol aqueous solution. As the mixed tocopherol, E mix A40 (trade name, manufactured by Eisai Co., Ltd., hereinafter referred to as mixed tocopherol) and other components were used commercially.
These high-pressure emulsified solutions were diluted with purified water or acid solution (0.75% tartaric acid-sodium tartrate buffer, pH 3) to a concentration of 0.01% as vitamin E, and the transmittance at 640 nm was measured. For each diluted solution, the transmittance after heat treatment at 90 ° C. for 3 minutes and the transmittance after standing at 45 ° C. for 1 month were also measured.
As a result, good transmittance was shown in all formulations (Table 1).
[0012]
[Table 1]
[0013]
Next, the transmittance | permeability of the vitamin E aqueous solution produced without implementing a high pressure process is hung up over as a comparative example below.
Comparative Example 1
With the formulation shown in Table 2, each component was mixed and stirred and mixed with a homomixer at 10000 rpm × 5 minutes while heating to about 70 ° C. to prepare a uniform aqueous solution.
These aqueous solutions were diluted with purified water or acid solution (0.75% tartaric acid-sodium tartrate buffer, pH 3) to a concentration of 0.01% as vitamin E, and the transmittance at 640 nm was measured. Moreover, the transmittance | permeability after performing the heat processing for 3 minutes at 90 degreeC about each diluted solution was also measured. As a result, the transmittance tended to be lower in any formulation compared to the formulation of Example 1 (Table 2).
[0014]
[Table 2]
[0015]
Examples of aqueous liquids when various fat-soluble drugs are used and examples of effects due to differences in composition components and production conditions are listed below.
Example 2 Various Vitamin Aqueous Solutions Using the same methods as in Example 1 with the formulations shown in Table 3, aqueous solutions of various vitamins were obtained. These solutions were diluted with purified water or acid solution (0.75% tartaric acid-sodium tartrate buffer, pH 3) to a concentration of 0.01% as each vitamin, and the transmittance at 640 nm was measured. Moreover, the transmittance | permeability after performing the heat processing for 3 minutes at 90 degreeC about each diluted solution was also measured.
As a result, the transmittance of various vitamin aqueous solutions was good in any formulation (Table 3).
[0016]
[Table 3]
[0017]
Example 3 Aqueous solutions of various fat-soluble drugs Using the same method as in Example 1 with the formulation shown in Table 4, aqueous solutions of various fat-soluble drugs were obtained. These solutions are diluted with purified water or acid solution (0.75% tartaric acid-sodium tartrate buffer, pH 3) to a concentration of 0.01% for each drug (formulation 13 is soybean oil), and the transmittance at 640 nm is increased. It was measured. Moreover, the transmittance | permeability after performing the heat processing for 3 minutes at 90 degreeC about each diluted solution was also measured.
As a result, the permeability of various fat-soluble drug aqueous solutions was good in any formulation (Table 4).
[0018]
[Table 4]
[0019]
Example 4 Effect on transmittance due to difference in treatment pressure Using the same method as in Example 1 with the formulation shown in Table 5, an aqueous mixed tocopherol solution was obtained. These solutions were diluted with purified water to a concentration of 0.01% as tocopherol, and the transmittance at 640 nm was measured. The processing pressure was 300, 500, 750, 1000, 1500 and 1800 kg / cm 2 . As a result, a favorable result was obtained when the treatment was performed at a pressure of 500 kg / cm 2 or more, and the transmittance was particularly good when the treatment was performed at a pressure of 750 kg / cm 2 or more.
[0020]
[Table 5]
[0021]
Example 5 Effect on transmittance due to difference in fatty acid chain species Using the same method as Example 1 with the formulation shown in Table 6, an aqueous mixed tocopherol solution was obtained. These solutions were diluted with purified water or acid solution (0.75% tartaric acid-sodium tartrate buffer, pH 3) to a concentration of 0.01% as vitamin E, and the transmittance at 640 nm was measured. Moreover, the transmittance | permeability after performing the heat processing for 3 minutes at 90 degreeC about each diluted solution was also measured.
As a result, when stearic acid or oleic acid was used as the fatty acid chain, the transmittance was good regardless of liquidity and heat treatment. When myristic acid or lauric acid was used, the transmittance was good when diluted with purified water (including during heat treatment) and immediately after dilution with acid solution, but diluted with acid solution and heated at 90 ° C. When the treatment was performed, the transmittance tended to decrease (Table 6).
[0022]
[Table 6]
[0023]
Example 6 Vitamin E aqueous solution using lecithin or lysolecithin An aqueous solution of mixed tocopherol was obtained using the same method as in Example 1 with the formulation shown in Table 7. These solutions were diluted with purified water or acid solution (0.75% tartaric acid-sodium tartrate buffer, pH 3) to a concentration of 0.01% as vitamin E, and the transmittance at 640 nm was measured. Moreover, the transmittance | permeability after performing the heat processing for 3 minutes at 90 degreeC about each diluted solution was also measured.
As a result, the transmittance was good in all formulations (Table 7).
[0024]
[Table 7]
[0025]
Example 7 Influence on transmittance due to difference in polyhydric alcohol Using the same method as in Example 1 with the formulation shown in Table 8, an aqueous mixed tocopherol solution was obtained. These solutions were diluted with purified water or acid solution (0.75% tartaric acid-sodium tartrate buffer, pH 3) to a concentration of 0.01% as vitamin E, and the transmittance at 640 nm was measured. Moreover, the transmittance | permeability after performing the heat processing for 3 minutes at 90 degreeC about each diluted solution was also measured.
As a result, the transmittance was good in all formulations (Table 8).
[0026]
[Table 8]
[0027]
Example 8 Sensory test Using the same method as in Example 1 with the formulation shown in Tables 9 and 10, an aqueous mixed tocopherol solution was obtained. In addition, commercially available vitamin E preparations having the formulations shown in Table 11 were prepared. These solutions were diluted with purified water or a commercially available drink to a concentration of 0.01% as vitamin E, respectively, and subjected to a sensory test.
Four skilled panelists spit out about 20 ml of each diluted solution in their mouths for about 5 seconds, and evaluated the taste and aroma in the following four stages. A: Does not affect the flavor of the product. ○: There is little effect on the flavor of the product. Δ: Affects the flavor of the product. X: It affects the flavor of the product and is not suitable for drinks.
The results are shown in Tables 9, 10 and 11.
[0028]
[Table 9]
[0029]
[Table 10]
[0030]
[Table 11]
Claims (8)
脂溶性物質が、ビタミン類及び/又は脂溶性薬物であり、
ビタミン類が、ビタミンA、EおよびK、またはそれらの誘導体から選ばれる1種以上であり、
脂溶性薬物がテプレノンまたはコエンザイムQ10であり、
乳化剤が、ステアリン酸デカグリセリル及び/またはリゾレシチンであり、
脂溶性物質に対する乳化剤の配合比が0.5〜1.5である、
脂溶性物質水性液剤。5-30% by weight of a fat-soluble substance, 5-30% by weight of an emulsifier, 30-85% by weight of a polyhydric alcohol and water were stirred and mixed at 60-80 ° C. with a mixer, and then a high-pressure homogenizer was used. A fat-soluble substance aqueous solution substantially free of fats and oils, characterized by being obtained by treating at 60 to 80 ° C. and 500 to 2000 kg / cm 2 ,
The fat-soluble substance is vitamins and / or fat-soluble drugs,
The vitamins are one or more selected from vitamins A, E and K, or derivatives thereof;
The fat-soluble drug is teprenone or coenzyme Q10,
The emulsifier is decaglyceryl stearate and / or lysolecithin,
The blending ratio of the emulsifier to the fat-soluble substance is 0.5 to 1.5.
Fat-soluble substance aqueous solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32519299A JP3880265B2 (en) | 1998-11-16 | 1999-11-16 | Aqueous solution of fat-soluble substances |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32566298 | 1998-11-16 | ||
JP10-325662 | 1998-11-16 | ||
JP32519299A JP3880265B2 (en) | 1998-11-16 | 1999-11-16 | Aqueous solution of fat-soluble substances |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000212066A JP2000212066A (en) | 2000-08-02 |
JP3880265B2 true JP3880265B2 (en) | 2007-02-14 |
Family
ID=26571758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP32519299A Expired - Fee Related JP3880265B2 (en) | 1998-11-16 | 1999-11-16 | Aqueous solution of fat-soluble substances |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3880265B2 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4756493B2 (en) * | 2001-05-17 | 2011-08-24 | 株式会社ビーエス・ラボ | Topical skin preparation |
JP4615814B2 (en) * | 2002-10-11 | 2011-01-19 | 小林製薬株式会社 | Liquid external preparation for cold medicine and method for producing the same |
US7470436B2 (en) | 2002-12-04 | 2008-12-30 | Nisshin Pharma Inc. | Water-soluble composition containing coenzyme Q10 |
JP4518042B2 (en) * | 2002-12-04 | 2010-08-04 | 日油株式会社 | Method for producing water-soluble composition containing coenzyme Q10 |
JP3833648B2 (en) * | 2002-12-04 | 2006-10-18 | 日本油脂株式会社 | Water-soluble composition containing coenzyme Q10 |
WO2004064543A1 (en) | 2003-01-17 | 2004-08-05 | Taiyo Kagaku Co., Ltd. | Compositions containing coenzyme q10 |
JP4567945B2 (en) * | 2003-01-17 | 2010-10-27 | 太陽化学株式会社 | Ubidecarenone formulation |
WO2005034913A1 (en) * | 2003-10-10 | 2005-04-21 | Eisai Co., Ltd. | Novel liquid preparation composition |
JP3970878B2 (en) * | 2003-12-10 | 2007-09-05 | 花王株式会社 | Method for producing oil-in-water emulsion composition |
JP2006056816A (en) * | 2004-08-19 | 2006-03-02 | Nof Corp | Pre-emulsion containing fat-soluble vitamins |
WO2006022187A1 (en) * | 2004-08-24 | 2006-03-02 | Nisshin Pharma Inc. | Coenzyme q10-containing composition |
WO2006030850A1 (en) * | 2004-09-15 | 2006-03-23 | San-Ei Gen F.F.I., Inc. | Method of preparing solution of lipid-soluble ingredient |
CN101119710B (en) | 2004-11-16 | 2013-03-27 | 生物利用股份有限公司 | High concentration self-microemulsifying coenzyme Q10 preparations for nutritional use |
JP2006141247A (en) * | 2004-11-17 | 2006-06-08 | Nisshin Pharma Inc | Medium composition for cell culture containing coenzyme Q10 |
JP2006143651A (en) * | 2004-11-19 | 2006-06-08 | Cosmetics Roorando Kk | Water-soluble cosmetic and food |
JP2006290841A (en) * | 2005-04-14 | 2006-10-26 | Nippon Zettoc Co Ltd | Method for producing cosmetic and cosmetic |
JP5199665B2 (en) * | 2005-06-15 | 2013-05-15 | 株式会社カネカ | Coenzyme Q10-containing water-soluble composition and process for producing the same |
JP2007015965A (en) * | 2005-07-06 | 2007-01-25 | Besubio:Kk | Water-soluble composition containing ubiquinones |
JP4662149B2 (en) * | 2005-11-16 | 2011-03-30 | 日本製粉株式会社 | Method for producing menthol-containing noodles |
WO2007080787A1 (en) * | 2006-01-12 | 2007-07-19 | Nisshin Pharma Inc. | Coenzyme q10-containing water-soluble compositions |
JP4644135B2 (en) * | 2006-02-09 | 2011-03-02 | 太陽化学株式会社 | Coenzyme Q10-containing composition |
JP4563438B2 (en) * | 2006-11-08 | 2010-10-13 | ジボダン エス エー | Transparent emulsified composition and transparent emulsified fragrance composition for alcoholic beverage or carbonated beverage |
JP5154805B2 (en) * | 2007-01-26 | 2013-02-27 | 江崎グリコ株式会社 | Dispersed hesperetin |
EP2172223B1 (en) | 2007-06-22 | 2020-12-16 | Kaneka Corporation | Composition containing physiologically active substance |
EP2172196B1 (en) | 2007-06-22 | 2020-03-25 | Kaneka Corporation | Composition containing coenzyme q10 |
KR101057623B1 (en) * | 2007-07-26 | 2011-08-19 | 주식회사 대웅제약 | Coenzyme Q10-containing self-emulsifying drug delivery system composition and method of manufacturing the same |
EP2192887A1 (en) * | 2007-08-29 | 2010-06-09 | Agency for Science, Technology And Research | Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use |
JP4970546B2 (en) * | 2007-10-03 | 2012-07-11 | アサヒグループホールディングス株式会社 | Granules, tablets and methods for producing them |
WO2009078245A1 (en) * | 2007-12-19 | 2009-06-25 | Foodtech Trading Co., Ltd. | Transparent emulsified composition and cosmetic and food containing the same |
JP2009149542A (en) | 2007-12-19 | 2009-07-09 | Foodtech Trading Co Ltd | Transparent emulsion composition, and cosmetics and foodstuffs containing it |
JP4869266B2 (en) * | 2008-03-03 | 2012-02-08 | 長谷川香料株式会社 | Beverage emulsion composition containing coenzyme Q10 and method for producing the same |
JP5203084B2 (en) * | 2008-07-30 | 2013-06-05 | 江崎グリコ株式会社 | Dispersed hesperetin |
JP5316160B2 (en) * | 2009-03-27 | 2013-10-16 | 日油株式会社 | Oil-in-water edible emulsion composition |
HK1200109A1 (en) * | 2012-02-27 | 2015-07-31 | 日本乐敦制药株式会社 | Ophthalmic composition |
WO2013183778A1 (en) * | 2012-06-08 | 2013-12-12 | ライオン株式会社 | Composition for mucous membranes |
JP2014114247A (en) * | 2012-12-11 | 2014-06-26 | Capsugel Belgium Nv | Oil-in-water type emulsion and method for producing the same |
JP5588048B1 (en) * | 2013-06-17 | 2014-09-10 | 高田香料株式会社 | Emulsified fragrance composition |
JP2014098014A (en) * | 2014-01-31 | 2014-05-29 | Agency For Science Technology & Research | Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use |
WO2017022811A1 (en) * | 2015-08-04 | 2017-02-09 | 日東薬品工業株式会社 | Emulsion composition for preventing or ameliorating snoring |
JP2018043990A (en) * | 2017-10-11 | 2018-03-22 | カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップCapsugel Belgium NV | Oil-in-water emulsion and method for producing the same |
-
1999
- 1999-11-16 JP JP32519299A patent/JP3880265B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2000212066A (en) | 2000-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3880265B2 (en) | Aqueous solution of fat-soluble substances | |
US6190680B1 (en) | Oily composition and process for producing the same | |
US9345250B2 (en) | Method for preparing solubilized composition containing oil-soluble substance | |
US11382980B2 (en) | Oil/fat composition containing polyunsaturated fatty acid | |
JP6393468B2 (en) | Oil composition containing polyunsaturated fatty acid | |
KR101061679B1 (en) | Water-soluble composition containing coenzyme # 10 | |
JP4044354B2 (en) | Composition having alcohol resistance, acid resistance and salt resistance and uses | |
KR101116899B1 (en) | Concentrated and diluted stable oil/water emulsions | |
JPH0867666A (en) | Powdery pharmaceutical preparation containing carotenoid and its production | |
JP2004091392A (en) | Water-insoluble component-containing composition for water dispersion and beverage | |
JP4910927B2 (en) | Astaxanthin-containing emulsion and production method | |
JP4644135B2 (en) | Coenzyme Q10-containing composition | |
JP3870740B2 (en) | Ceramide dispersion, production method and application | |
TWI343255B (en) | ||
JP2000157168A (en) | Oily composition and method for producing the same | |
JPWO2006030850A1 (en) | Method for preparing solubilized product of fat-soluble component | |
JPH0693996B2 (en) | Emulsified composition | |
JP2004261005A (en) | Ubidecarenone preparation | |
JP2006045061A (en) | Ceramides-containing composition, ceramides-containing aqueous preparation, and food and beverage, cosmetic and external preparation for skin, each containing the same composition or the same preparation | |
JP2004154060A (en) | Phosphatidylserine solubilizing solution, production method and use | |
JP2015044780A (en) | Solubilizer | |
KR20110130036A (en) | Astaxanthin-containing nanoemulsion composition | |
JP4019402B2 (en) | Oil-soluble substance solubilized composition, production method thereof, and food and drink containing the same | |
JP2004189749A (en) | Cosmetic composition | |
JPH08323189A (en) | Aqueous composition in which an oil-soluble substance is solubilized or dispersed |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050325 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050627 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050826 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051102 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20051208 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20060711 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061107 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061107 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |